Teva Pharmaceutical Industries Limited (VIE:TEVA)
| Market Cap | 37.36B +95.0% |
| Revenue (ttm) | 15.16B +4.1% |
| Net Income | 617.96M |
| EPS | 0.53 |
| Shares Out | n/a |
| PE Ratio | 60.45 |
| Forward PE | 12.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 31.50 |
| Previous Close | 31.30 |
| Day's Range | 31.30 - 31.60 |
| 52-Week Range | 15.50 - 32.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About VIE:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi's 2026 Global Healthcare Conference
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and o...
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
Selling at a loss does not end your rights. TEVA investors hurt by the roughly 8.74% decline that followed the immediate exit of Teva's Global R&D chief may be eligible to seek recovery.
Teva Pharmaceutical Industries Limited Announces Departure of Chief Medical Officer Dr. Eric Hughes on November 17, 2026
Teva Pharmaceutical Industries Limited announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, notified the company on November 17, 2026, of his intention to re...
Teva Announces R&D Leadership Transition As Chief Medical Officer Departs
(RTTNews) - Teva Pharmaceuticals Industries (TEVA) announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, will leave the company after accepting a position out...
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unch...
EFG, SPOT, TEVA, SE: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE Growth ETF (Symbol: EFG) where we have detected an a...
Teva settles US states' drug price-fixing case
Teva Pharmaceutical Industries has settled long-running litigation by most US states accusing the drugmaker and dozens of other defendants of conspiring to fix prices on dozens of generic drugs.
Teva Pharmaceutical Wins FDA Approval For IGALMI Sublingual Film For At-Home Use
(RTTNews) - Monday, Teva Pharmaceutical Industries Limited (TEVA) announced that the U.S. Food and Drug Administration has approved IGALMI, also known as dexmedetomidine, sublingual film for at-home u...
Alkermes plc Enters Settlement Agreement With Teva Over LYBALVI Patent Litigation
On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited, two wholly-owned indirect subsidiaries of Alkermes plc, entered into a Confidential Settlement and License Agreement with Teva ...
Teva CEO Richard Francis goes one-on-one with Jim Cramer
Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk its first R&D day, where it is seeing growth opportunities, its individual offerings, and more.
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.
Teva Pharmaceutical Industries Transcript: R&D Day 2026
The strategy centers on validated science, differentiated products and faster development, with a broad pipeline and launches planned through 2030. Innovative revenue is projected at $6B–$7B in 2030, supported by increased R&D investment and disciplined capital allocation.
Teva Pharmaceutical Industries Slides: FY 2026
Teva Pharmaceutical Industries has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 11, 2026.
Teva Pharmaceutical Industries Press release: FY 2026
Teva Pharmaceutical Industries issued a press release on November 11, 2026, disclosing material business information to investors.
Teva Pharma Issues Innovative Medicines Revenue Outlook
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) said it targets to generate $6-7 billion in innovative medicines revenue by 2030. The company projects innovative gross margins target of above 7...
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
IEFA, SPOT, TEVA, NBIS: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue.
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by ...
Teva (TEVA) Q3 2026 Earnings Call Transcript
Innovative drugs offset generic declines as Teva raises full-year guidance.
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyski...
Teva Pharmaceutical Industries Limited Reports Q3 2026 Financial Results and Raises 2026 Outlook for Key Innovative Brands
Teva Pharmaceutical Industries Limited reported Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms. This decrease primarily reflected lower...
Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat
Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.
Teva Pharmaceutical Industries Earnings Call Transcript: Q3 2026
Q3 revenue fell 2%, while non-GAAP EPS rose 10% and innovative brands grew strongly. FY 2026 guidance increased, and investment-grade ratings and debt reduction support the growth and pipeline investment plan.
Teva Pharmaceutical Industries Slides: Q3 2026
Teva Pharmaceutical Industries has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.